AU2001245535A1 - Human fgf-23 gene and gene expression products - Google Patents
Human fgf-23 gene and gene expression productsInfo
- Publication number
- AU2001245535A1 AU2001245535A1 AU2001245535A AU4553501A AU2001245535A1 AU 2001245535 A1 AU2001245535 A1 AU 2001245535A1 AU 2001245535 A AU2001245535 A AU 2001245535A AU 4553501 A AU4553501 A AU 4553501A AU 2001245535 A1 AU2001245535 A1 AU 2001245535A1
- Authority
- AU
- Australia
- Prior art keywords
- gene
- expression products
- human fgf
- gene expression
- fgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18785400P | 2000-03-08 | 2000-03-08 | |
US60/187,854 | 2000-03-08 | ||
US23336800P | 2000-09-18 | 2000-09-18 | |
US60/233,368 | 2000-09-18 | ||
US25164900P | 2000-12-05 | 2000-12-05 | |
US60/251,649 | 2000-12-05 | ||
PCT/US2001/007469 WO2001066596A2 (en) | 2000-03-08 | 2001-03-07 | Human fgf-23 gene and gene expression products |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001245535A1 true AU2001245535A1 (en) | 2001-09-17 |
Family
ID=27392306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001245535A Abandoned AU2001245535A1 (en) | 2000-03-08 | 2001-03-07 | Human fgf-23 gene and gene expression products |
Country Status (3)
Country | Link |
---|---|
US (1) | US20030105302A1 (en) |
AU (1) | AU2001245535A1 (en) |
WO (1) | WO2001066596A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2233571B1 (en) | 2000-08-11 | 2012-11-07 | Kyowa Hakko Kirin Co., Ltd. | Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same |
US20040171825A1 (en) * | 2001-04-26 | 2004-09-02 | Lydie Bougueleret | Human fibroblast growth factor-related compositions |
KR101016476B1 (en) | 2001-12-28 | 2011-02-24 | 교와 핫꼬 기린 가부시키가이샤 | Antibodies Against Fibroblast Growth Factor 23 |
WO2003059270A2 (en) * | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
ES2365852T3 (en) * | 2003-11-07 | 2011-10-11 | Novartis Ag | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS. |
US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
AU2012279237B2 (en) | 2011-07-01 | 2016-09-29 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
JP6403685B2 (en) | 2012-12-27 | 2018-10-17 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | Methods of regulating bile acid homeostasis and treating bile acid disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
NZ718962A (en) | 2013-10-28 | 2019-12-20 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
US9738716B2 (en) | 2014-01-24 | 2017-08-22 | Ngm Biopharmaceuticals, Inc. | Beta klotho binding proteins and methods of use thereof |
WO2015149069A1 (en) | 2014-03-28 | 2015-10-01 | New York University | Fgf23 fusion proteins |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
RU2729161C2 (en) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Pharmaceutical compositions containing peptide versions, and methods of using them |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073454A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU761340B2 (en) * | 1998-06-02 | 2003-06-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000060085A1 (en) * | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
EP1246843A1 (en) * | 2000-01-05 | 2002-10-09 | ZymoGenetics, Inc. | Novel fgf homolog zfgf12 |
CA2398603A1 (en) * | 2000-02-15 | 2001-08-23 | Amgen, Inc. | Fibroblast growth factor-23 molecules and uses thereof |
-
2001
- 2001-03-07 US US09/802,154 patent/US20030105302A1/en not_active Abandoned
- 2001-03-07 AU AU2001245535A patent/AU2001245535A1/en not_active Abandoned
- 2001-03-07 WO PCT/US2001/007469 patent/WO2001066596A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001066596A2 (en) | 2001-09-13 |
WO2001066596A3 (en) | 2002-03-28 |
US20030105302A1 (en) | 2003-06-05 |
WO2001066596A9 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001249125A1 (en) | Human fgf-23 gene and gene expression products | |
AU2001245535A1 (en) | Human fgf-23 gene and gene expression products | |
AU2001285047A1 (en) | Human genes and gene expression products | |
AU2001245619A1 (en) | Human genes and gene expression products | |
AU6069300A (en) | Novel human genes and gene expression products | |
AU4187499A (en) | Human genes and gene expression products v | |
AU4053699A (en) | Novel human genes and gene expression products | |
AU7748200A (en) | Hypoxia-related human genes, proteins, and uses thereof | |
AU2002237240A1 (en) | Histone deacetylase-related gene and protein | |
AU3072500A (en) | Rhamnosyl-transferase gene and uses thereof | |
AU2001282288A1 (en) | Kaolin products and their use | |
AU1101901A (en) | Human fgf-20 gene and gene expression products | |
AU4329300A (en) | Human mesenchymal dnas and expression products | |
AU2001226922A1 (en) | Cancer associated genes and their products | |
AU2001270478A1 (en) | Gene expression in biological conditions | |
AU2001274566A1 (en) | Novel protein and dna thereof | |
AU2001287269A1 (en) | Human genes and expression products | |
AU6263999A (en) | Human genes and gene expression products | |
AU2001268053A1 (en) | Human sparc-homologous (hsparc-h1) gene and methods and uses thereof | |
AU2001264955A1 (en) | Human cyslt2 nucleic acids, polypeptides, and uses thereof | |
AU1894601A (en) | Novel gene and use thereof | |
AU2001264245A1 (en) | Novel enzyme gene and its expression product | |
AU6424501A (en) | Novel enzyme gene and its expression product | |
AU6773200A (en) | Egfh2 genes and gene products | |
AU3900000A (en) | Human fgf gene and gene expression products |